Back to Search
Start Over
Escape Velocity—the Launch of Microbiome Therapies.
- Source :
-
Journal of Infectious Diseases . 7/15/2024, Vol. 230 Issue 1, p2-4. 3p. - Publication Year :
- 2024
-
Abstract
- Food and Drug Administration approval of the first microbiome therapies represents a true expansion the treatment paradigm for Clostridioides difficile but raises new questions about the future role of fecal microbiota transplantation. The authors outline the advances in microbiome therapeutic development that have addressed fecal microbiota transplantation's (FMT's) inherent limitations of safety and scalability. The authors also suggest that as microbiome therapeutic development continues for other indications, FMT will likely remain a necessary model of human microbiota dynamics for translational research. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 00221899
- Volume :
- 230
- Issue :
- 1
- Database :
- Academic Search Index
- Journal :
- Journal of Infectious Diseases
- Publication Type :
- Academic Journal
- Accession number :
- 178738681
- Full Text :
- https://doi.org/10.1093/infdis/jiae099